Anew Medical (WENA) said Tuesday it plans to advance its patented Klotho gene therapy program for neurodegenerative disorders.
Anew said it has "compelling initial data" suggesting that elevated levels of Klotho contributes to longer, healthier lifespans, while people with depleted levels of the gene "are more susceptible to neurodegenerative disorders such as ALS, Alzheimer's, and Parkinson's Disease."
The company said it plans to advance its program in clinical trials, in the commercialization of a diagnostic that will enable doctors to quantify levels of Klotho gene and protein isoforms in blood samples, and in age-related disorders such as memory loss, osteoporosis, and sarcopenia.
Anew Medical rose 48% to $2.14 in premarket trading.
Price: 2.3800, Change: +0.93, Percent Change: +64.14
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。